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Abstract
Background
Costly biologicals in palliative oncology are emerging at a rapid pace. For example, in
patients with advanced esophageal squamous cell carcinoma addition of cetuximab to a
palliative chemotherapy regimen appears to improve survival. However, it simultaneously
results in higher costs. We aimed to determine the incremental cost-effectiveness ratio of
adding cetuximab to first-line chemotherapeutic treatment of patients with advanced esoph-
ageal squamous cell carcinoma, based on data from a randomized controlled phase II trial.
Methods
A cost effectiveness analysis model was applied based on individual patient data. It
included only direct medical costs from the health-care perspective. Quality-adjusted life-
years and incremental cost-effectiveness ratios were calculated. Sensitivity analysis was
performed by a Monte Carlo analysis.
Results
Adding cetuximab to a cisplatin-5-fluorouracil first-line regimen for advanced esophageal
squamous cell carcinoma resulted in an the incremental cost-effectiveness ratio of
€252,203 per quality-adjusted life-year. Sensitivity analysis shows that there is a chance of
less than 0.001 that the incremental cost-effectiveness ratio will be less than a maximum
willingness to pay threshold of €40,000 per quality-adjusted life-year, which is representa-
tive for the threshold used in The Netherlands and other developed countries.
Conclusions
Addition of cetuximab to a cisplatin-5-fluorouracil first-line regimen for advanced esoph-
ageal squamous cell carcinoma is not cost-effective when appraised according to currently
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Background
The use of biologicals in palliative oncology is expanding at a rapid pace. These new therapeu-
tic agents may improve patients’ survival and quality of life. However, the money spend on
biologicals is expected to increase at a faster rate than the overall spending growth on pharma-
ceuticals and is projected to represent roughly one fifth of the total costs by 2017 [1]. It would
be beneficial for drug companies, policy makers, physicians and patients alike when the cost-
effectiveness of these biologicals would become apparent at an early stage of development.
A good example of a carcinoma for which biologicals are being studied in palliative phase II
trials is esophageal squamous cell carcinoma (ESCC). ESCC is the predominant form of esoph-
ageal carcinoma worldwide, and most patients are diagnosed in advanced stages not amenable
to curative treatment [2–4]. Palliative therapy consists of chemotherapy or (chemo-)radiation
therapy, management of pain, and achieving optimal nutrition. Currently survival in these
patients receiving palliative care remains poor.
Lorenzen et al. conducted a phase II trial in 62 patients with non-resectable epidermal
growth factor receptor (EGFR)-expressing ESCC [5]. This trial showed that addition of cetuxi-
mab (Erbitux, Merck Serono, Geneva, Switzerland) in palliative treatment of ESCC is likely to
prolong survival. The median progression-free survival increased from 3.6 months (95% confi-
dence interval (CI) 1.0–6.2) to 5.9 months (95% CI 3.8–8.0). The median overall survival
increased from 5.5 months (95% CI 1.9–9.1) to 9.5 months (95% CI 8.4–10.6). The three
adverse events that occurred more often in the cetuximab arm were neutropenia (22% vs 13%),
diarrhea (16% vs 0%), and nausea (13% vs 3%), while fatigue decreased (3% vs 10%) [5].
The cost-effectiveness of cetuximab as palliative treatment has not been investigated in
ESCC, but has been assessed for other malignancies. Hannouf et al. [6]. estimated that adding
cetuximab to platinum-based chemotherapy for squamous cell carcinoma of the head and neck
(SCCHN) resulted in a cost-utility ratio of €249,888 per quality adjusted life year (QALY). In
addition an incremental cost-effectiveness ratio (ICER) of €242,494 per QALY was reported by
the National Institute for Care and health Excellence (NICE) after exploratory analysis using
alternative assumptions and parameters in the economic model of the treatment of SCCHN
with cetuximab [7]. In metastasized KRAS wild type colorectal carcinomas, an ICER of
€112,707 per QALY was reported [8]. All these studies with incurable patients receiving cetuxi-
mab show ICERs above a maximum willingness to pay threshold of €40,000. This threshold is
representative for The Netherlands and other developed countries [9–14].
Phase III trials investigating the effectiveness of adding cetuximab to palliative therapy of
ESCC were started after the publication of Lorenzen et al. [15]. Although the addition of cetux-
imab seems to offer a health benefit, it might have an ICER above the current maximum will-
ingness to pay threshold. Early estimation of the ICER would give early insight into the costs of
the therapy regimen and hence the probability that the drug will be reimbursed. If there is too
much of a gap between effectiveness and costs, informed decision-making could question the
costly development of a drug that will have a hard time to be commercially viable and, impor-
tantly, early information sharing would spare the public from developing false expectations.
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This paper aims to calculate the expected mean ICER of adding cetuximab to the standard
palliative treatment of ESCC in a Dutch health-care setting, based on published data from a
phase II trial [5]. It shows that the addition of cetuximab is not cost-effective.
Methods
Framework of cost-effectiveness analysis
The cost-effectiveness analysis was based on data from the study performed by Lorenzen et al.
[5]. A linear model was used. Two clinical outcome measures, namely mean progression free
survival (PFS) and mean overall survival (OS), were used in addition to an approximation of
overall costs, in order to calculate ICERs. The cost-effectiveness analysis assumed the health-
care perspective, including only direct medical costs. Modelling was done using Microsoft
Excel (Microsoft Corporation, Redmond, WA).
One-way sensitivity analysis
A one-way sensitivity analysis was conducted by taking all input variables of the model and
varying them by 10% in both directions. When varying one input variable, other input vari-
ables were kept constant.
Probabilistic sensitivity analysis
The probabilistic sensitivity analysis was performed using a Monte Carlo simulation using
Microsoft Excel (Microsoft Corporation, Redmond, WA). For this analysis, 1,000 simulated tri-
als were run, where the values for the OS and PFS of both arms were sampled at random from
normalized probability distributions based on the trial sample means and their standard devia-
tion. By using the standard deviation of the mean values the variation of the sample means esti-
mate of the population mean was taken into account. Other parameters of the model were kept
constant. This generated the mean costs and mean survival benefit for 1,000 simulated trials.
Patients
In the study of Lorenzen et al. [5], 62 patients were randomly assigned to the cetuximab, cis-
platin, and fluorouracil arm (n = 32) or to the cisplatin and fluorouracil arm (n = 30). The pro-
tocol of the study of Lorenzen et al. was approved by the ethics committee for human research
at the Technische Universität München, Munich, Germany, and conformed to the principles
of the Declaration of Helsinki and its subsequent amendments. The analyses presented in this
study fall under the same protocol. All patients gave written informed consent. Patient records/
information was anonymized and de-identified prior to analysis. The patients were at least 18
years of age, had histologically confirmed and EGFR-expressing advanced non-resectable
ESCC. They had not received (neo)adjuvant chemotherapy within six months of enrollment
into the study and had not had prior chemotherapy for recurrent or metastatic disease. Their
Eastern Cooperative Oncology Group performance status (ECOG PS) had to be one or less,
creatinine clearance had to be above 70 ml/min. They had to have adequate hepatic function,
bone marrow function, and a lesion measurable in one dimension of at least one cm in diame-
ter detected by computed tomography (CT) scan was required. Exclusion criteria were a second
malignancy, uncontrolled infection, a neuropathy grade more than one, and pregnancy or lac-
tation. Median follow-up time was 21.5 months. Both groups were well balanced with respect
to age, tumor differentiation, and intensity of EGFR staining. However, there was a marked
difference in the gender balance between the arms with the cetuximab arm containing more
female patients. More than 30% of patients in each arm had either prior surgery, radiotherapy,
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or both. In contrast, only 13% of patients in each arm had received prior systemic chemother-
apy [5].
Therapy regimen
For a maximum of six 29-day cycles, patients received cisplatin 100 mg/m2, day 1, plus fluoro-
uracil 1,000 mg/m2, days 1–5, either alone or in combination with cetuximab. Cetuximab was
initially dosed at 400 mg/m2, followed by 250 mg/m2 weekly thereafter [5]. The modelled
therapy regimen was constructed to take treatment discontinuation into account, the level of
treatment discontinuation was chosen so as to assume a mean cetuximab use equal to that cal-
culated for the phase II trial (see results section).
Determination of QALYs
PFS and OS figures were used from the study of Lorenzen et al. The authors reported median
OS and PFS times. Using individual patient data, mean OS and PFS times were calculated, as
these data were necessary to calculate the ICER of the proposed therapy regimen. The utility
score during PFS was calculated. Asymptomatic adenocarcinoma of the esophagus was associ-
ated with a utility score of 0.77, symptomatic adenocarcinoma of the esophagus was associated
with a utility score of 0.675 [16, 17]. Since most patients were diagnosed because they presented
themselves with symptoms, the utility score of symptomatic disease was used, i.e. 0.675. The
utility score during disease progression was defined as the average of the utility score at death,
which is zero, and the utility score during PFS. This approach reflects the assumption that the
utility score linearly declines from the point of progression to the point of passing away, see
Fig 1 for a schematic representation of the assumptions used. QALYs were calculated by:
PFS  utility score during PFS + (OS − PFS)  utility score during disease progression:
PFS × 0.675 + (OS − PFS) × 0.675. The amount of QALYs gained was calculated by taking the
amount of QALYs calculated for the intervention group minus the amount of QALYs calcu-
lated for the control group.
Determination of costs
An estimate was made of the medical resource usage that resulted from the incremental cost of
adding cetuximab to the standard treatment. Unless otherwise specified, unit costs were
obtained from the Dutch manual for cost-effectiveness research 2010 [18]. The cost of cetuxi-
mab for an average patient was calculated. The cost of cetuximab in 2007 was €207 per 100 mg
in the Netherlands, and €237,20 in 2009 [19]. The model accounted for: value attributed tax,
duration of treatment, the increased dose for the first treatment (400 versus 250 mg), the male
female difference in dosage, the relative proportion of both sexes affected by ESCC, and the
amount of treatment discontinuation. The cost of an outpatient visit was estimated to be €251
[18]. The number of outpatient clinic visits was calculated. Duration of therapy and the num-
ber of outpatient visits that can be combined with visits for chemotherapy were accounted for.
The incremental cost of these combined visits was estimated. Lorenzen et al. screened for
EGFR expressing tumor patients [5]. Screening for a subset of eligible patients significantly
contributes to therapy cost, increasing with decreasing biomarker frequencies [16]. The cost of
evaluation of EGFR expression (€750) was based on the reimbursement for such a test in the
Dutch healthcare system. It was assumed that 60% of patients have EGFR expressing tumors
[20–22]. Although all patients have to be screened. Incremental cost for housing and deprecia-
tion of goods (6.5%) and overhead (35.5%) were accounted for. Possible costs associated with
an increase in adverse events were not accounted for. All costs and effects were converted to
the price level of 2009 according to the general Dutch consumer price index [23]. Results of
Cost-Effectiveness of Cetuximab for Advanced ESCC
PLOSONE | DOI:10.1371/journal.pone.0153943 April 21, 2016 4 / 10
other studies, reported in CAD and Pound Sterling, were converted to euros using the purchas-
ing power parity index of the year closest to the year in which the study outcome was reported
[24]. A cost-effectiveness ratio below €40,000 per gained QALY was assumed to be acceptable.
This threshold is representative for the willingness to pay threshold in The Netherlands and
other developed countries [9–14]. The time horizon of the base case model was 0.9 years.
Because of this short time horizon, neither costs nor clinical outcomes were discounted.
Results
Lorenzen et al. reported a median OS of 5.5 and a median PFS of 3.6 months for the CF arm as
well as a median OS of 9.5 and a median PFS of 5.9 months for the CET CF arm. This translates
into a mean OS of 8.6 and a mean PFS of 5.6 months for the CF arm as well as a mean OS of
10.8 and a mean PFS of 7.1 for the CET CF arm. The median cumulative dose of cetuximab per
patient was reported to be 8 690mg. The mean cumulative dose of cetuximab per patient was
recalculated. This resulted in a mean cumulative dose of 6,443mg cetuximab per patient. Subse-
quently, the level of treatment discontinuation was chosen so as to assume a mean cetuximab
use of 6,444mg.
The mean survival gained by the addition of cetuximab to standard chemotherapy was
0.187 life years and 0.105 QALYs. The mean incremental cost was calculated to be € 26,459 per
treated patient. The incremental costs included the costs of cetuximab, additional day treat-
ment facilities, and the cost of evaluation EGFR status, in order of impact. Adding cetuximab
to a cisplatin-5-fluorouracil first-line regimen for advanced ESCC resulted in a mean ICER of
€252,203 per QALY.
A one-way sensitivity analysis was conducted by taking all input variables of the model and
varying them by 10% in both directions. The resulting ICERs were depicted in a tornado plot,
see Fig 2. The input extracted from the phase II trial, had most effect on the determination of
Fig 1. Schematic representation of the health states and utility scores used in the linear model. At diagnosis a utility score of 0.675 was assumed. This
utility score remains stable during progression free survival. During progressive disease, it was assumed that the utility score declines linearly from 0.675 to 0
at the time of death.
doi:10.1371/journal.pone.0153943.g001
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the ICER. Other factors of influence were the quality of life assumption used, the amount of
cetuximab used, and the price of cetuximab.
A probabilistic sensitivity analysis was performed by conducting a Monte Carlo analysis,
results are shown in Fig 3. Each point represents one of the 1,000 trials runs. The data extracted
from the phase II trial had most influence on the determination of the ICER in the one-way
sensitivity analysis. Therefore, with respect to the input data for the OS and PFS of both arms,
each input was assigned a random value. This was based on the mean and standard deviation
extracted from the individual patient data. Other input data was kept constant. The solid diago-
nal line indicates the €40,000 per QALY gained willingness to pay threshold. Trial points that
fall to the left and above this diagonal line indicate a cost-effectiveness of that trial run above
the given maximum willingness to pay threshold level. This analysis shows that P< 0.001 of
the ICER being below a maximum willingness to pay threshold of €40,000.
Discussion
The mean ICER of adding cetuximab to a cisplatin-5-fluorouracil first-line palliative regimen
for ESCC, is €252,203 per QALY gained. By performing a Monte Carlo analysis we showed
that there’s a chance of less than 0.001 that the ICER would be below a threshold of acceptable
cost per QALY of €40,000. This threshold is representative for the willingness to pay threshold
in the Netherlands. Thus, the therapy regimen will at present not be considered cost-effective
Fig 2. Tornado plot of a one-way sensitivity analysis. Input variables were tested in a one-way sensitivity analysis. These variables were either decreased
by 10% of the value used in the base case model, or increased 10% from their original value. The bars represent the range of the ICER if the variable lies
between -10% and +10% of its assumed value in the base case model. The ICER form the base case model was indicated by the vertical dotted line.
doi:10.1371/journal.pone.0153943.g002
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by decision makers and, in all probability, will not be reimbursed within the regulated Dutch
health insurance system.
In the United Kingdom, the NICE uses an unpublished threshold of £30,000 (€36,997) in
2012 [12, 13]. In Japan the willingness to pay threshold is 5,000,000 JPY (€43,014) in 2010. In
the United States of America the threshold is US$ 62,000 (€46,617) in 2010 [14]. This indicates
the threshold used, of €40,000, is representative for a willingness to pay threshold used in many
developed countries [9, 10]. The price of cetuximab is the dominant driver of the overall costs.
Although biosimilars are expected to become available at a 15% to 30% lower prices, substitu-
tion of cetuximab with a biosimilar would not make the therapy regimen cost effective [25]. In
fact, due to testing of EGFR overexpression and the need for additional day treatments, the
ICER was modelled to become €45.907 if cetuximab would be available for free. The ICER that
we calculated is in line with previous findings for SCCHN, which has similarities in etiology
and pathology, [6, 7, 26] and for KRAS wild type colorectal carcinomas [8, 27]. Cost-effective-
ness studies after phase II trials have been previously performed [28]. This method has
been discussed related to the topic of streamlining the drug development process and early
Fig 3. Scatter plot of Monte Carlo sensitivity analysis.One thousand repeated random samplings from the model described are depicted in the figure.
Each sampling is depicted by one dot and represents the average QALY gained and the incremental cost of that sampling from the model. The vertical line
separates the plane (to the left), for which the intervention is not effective. With the plane to the right for which the intervention is effective. The inclining line
depicts the maximumwillingness to pay threshold at an ICER of €40,000 per QALY gained. This line separates the plane above it, for which the intervention
is effective but not cost effective, with the plane below, for which the intervention is effective and cost effective.
doi:10.1371/journal.pone.0153943.g003
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estimation and decision making for reimbursement in 2001 and 2003 [29, 30]. However, no
widespread adaptation has taken place.
This study has certain limitations. Quality of life of the patients receiving cetuximab could
be affected negatively by side effects. This has not been accounted for in the model. Other limi-
tations of this study are the lack of data on utility scores, both during PFS and after progression
of ESCC, therefore data for adenocarcinoma of the esophagus was used. Vial wastage and pos-
sible discounts negotiated by hospitals have not been accounted for. Since we did not have
access to actual cost data from patient enrolled in this phase II study, another limitation is the
use of costs that were taken from a manual for cost-effectiveness.
The results of the phase II trial remain promising despite the considered lack in cost effec-
tiveness. Selecting patients for whom the drug has the most effect will increase treatment effec-
tiveness and remove the burden of side effects from unselected patients. The EGFR staining
pattern could be used as a criterion for selection. It has been correlated with poor prognosis in
ESCC in a western European population [20]. Tumor specific EGFR downstream signaling
mutations in KRAS, [8, 31] BRAF, [31, 32] PTEN, [33] and PIK3CA [31, 34] cause reduced ben-
efit of cetuximab therapy in colon carcinoma patients. Germ line polymorphisms could also
predict response to treatment, as has been studied in colorectal cancer [35–38]. These options
for selection of patients are still speculative and should be investigated further.
Conclusions
Addition of cetuximab to a cisplatin-5-fluorouracil first-line regimen for advanced ESCC is not
cost-effective when appraised according to currently accepted criteria. Cost-effectiveness anal-
yses using outcome data from early clinical trials (i.c. a phase II trial) enable pharmaceutical
companies and policy makers to gain early insights into whether a new drug meets the current
eligibility standards for reimbursement and thereby potential allowance for use in clinical
practice.
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